NCT05398614

SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies

Early Clinical Study of SENL101 Autologous T Cell Injection in the Treatment of Adult Patients With Relapsed or Refractory CD7+ Hematolymphoid Malignancies

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Hebei Senlang Biotechnology Inc., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory CD7+ hematolymphoid malignancies.

Detailed description

Main research purposes: To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory CD7+ hematolymphoid malignancies. Secondary research purposes: To preliminarily evaluate the efficacy, pharmacokinetics and pharmacodynamics of SENL101 in the treatment of patients with relapsed or refractory CD7+ hemolymphoid malignancies. Exploratory research purpose： 1. To explore the immunogenicity of SENL101； 2. T cell NK cell recovery time after treatment； 3. Other indicators of interest to researchers。

Conditions

• T-ALL
• Lymphoma, T-Cell

Interventions

Type	Name	Description
BIOLOGICAL	SENL101	Patients will be treated with CD7 CAR-T cells

Timeline

• Start date: 2022-05-01
• Primary completion: 2023-12-30
• Completion: 2024-06-30
• First posted: 2022-06-01
• Last updated: 2022-06-01

Locations

1 site across 1 country: China